JPWO2021006212A1 - - Google Patents

Info

Publication number
JPWO2021006212A1
JPWO2021006212A1 JP2021530676A JP2021530676A JPWO2021006212A1 JP WO2021006212 A1 JPWO2021006212 A1 JP WO2021006212A1 JP 2021530676 A JP2021530676 A JP 2021530676A JP 2021530676 A JP2021530676 A JP 2021530676A JP WO2021006212 A1 JPWO2021006212 A1 JP WO2021006212A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021530676A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021006212A1 publication Critical patent/JPWO2021006212A1/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells
    • C12N5/163Animal cells one of the fusion partners being a B or a T lymphocyte
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • C12N5/12Fused cells, e.g. hybridomas
    • C12N5/16Animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2021530676A 2019-07-08 2020-07-03 Pending JPWO2021006212A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019127110 2019-07-08
PCT/JP2020/026218 WO2021006212A1 (ja) 2019-07-08 2020-07-03 ハイブリドーマおよびその製造方法、並びにモノクローナル抗体およびその製造方法

Publications (1)

Publication Number Publication Date
JPWO2021006212A1 true JPWO2021006212A1 (ja) 2021-01-14

Family

ID=74114224

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021530676A Pending JPWO2021006212A1 (ja) 2019-07-08 2020-07-03

Country Status (4)

Country Link
US (1) US20220251518A1 (ja)
EP (1) EP3998280A4 (ja)
JP (1) JPWO2021006212A1 (ja)
WO (1) WO2021006212A1 (ja)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JPH05227970A (ja) 1992-02-19 1993-09-07 Chugai Pharmaceut Co Ltd ヒトインターロイキン−6受容体に対する再構成ヒト抗体
JPH06209769A (ja) 1993-01-18 1994-08-02 Giichi Sado ラットリンパ節細胞を用いた雑種細胞の作製
US7439330B2 (en) * 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
WO2010012004A2 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of California Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence
WO2008127347A1 (en) * 2006-07-21 2008-10-23 Diadexus, Inc. Pro115 antibody compositions and methods of use
CA2670696A1 (en) * 2006-11-27 2008-06-05 Diadexus, Inc. Ovr110 antibody compositions and methods of use
ME01026B (me) * 2007-11-16 2012-10-20 Univ Rockefeller Antitijela specifična za protofibrilni oblik beta-amiloid proteina
JP2009284771A (ja) 2008-05-27 2009-12-10 Takara Bio Inc 抗体産生細胞の作製方法
CA2747644C (en) * 2008-12-19 2023-01-24 Ablynx N.V. Method for generation of immunoglobulin sequences
SI2448968T1 (sl) * 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
US9714298B2 (en) * 2012-04-09 2017-07-25 Daiichi Sankyo Company, Limited Anti-FGFR2 antibodies and methods of use thereof for treating cancer
KR20220019839A (ko) * 2013-10-08 2022-02-17 다이이찌 산쿄 가부시키가이샤 항 fgfr2 항체와 타제의 조합
CA3048601A1 (en) * 2016-12-26 2018-07-05 Kyowa Hakko Kirin Co., Ltd. Antibody which binds to myelin oligodendrocyte glycoprotein
JP2019127110A (ja) 2018-01-23 2019-08-01 三菱電機株式会社 車両制御装置及び車両制御システム

Also Published As

Publication number Publication date
EP3998280A4 (en) 2023-06-21
EP3998280A1 (en) 2022-05-18
WO2021006212A1 (ja) 2021-01-14
US20220251518A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
BR112019017762A2 (ja)
BR112021017339A2 (ja)
BR112019016141A2 (ja)
BR112021017939A2 (ja)
BR112021017738A2 (ja)
BR112021017892A2 (ja)
BR112021017782A2 (ja)
AU2020104490A5 (ja)
BR112021017637A2 (ja)
BR112021008711A2 (ja)
BR112019016142A2 (ja)
BR112019016138A2 (ja)
BR112021017728A2 (ja)
BR112021017234A2 (ja)
BR112021017355A2 (ja)
BR112021017703A2 (ja)
BR112021017173A2 (ja)
BR112021018584A2 (ja)
BR112021017083A2 (ja)
BR112021015080A2 (ja)
BR112021012348A2 (ja)
BR112021013944A2 (ja)
BR112021013128A2 (ja)
BR112021018484A2 (ja)
BR112021016821A2 (ja)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240903